Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGXT | P21549 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | NCF1 | P14598 | 1/20 | 0.41 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | GAA | P10253 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4181983 | 0.83 | AGXT (0.60) | AGXTHTR2AHTR6ADRA2CHTR3A | |
| SCHEMBL3585755 | 0.82 | NCF1 (0.55) | HTR2AHTR6NCF1ADRA2CCHKA | |
| SCHEMBL14922318 | 0.72 | CHKA (0.59) | AGXTNCF1ADRA2CCHKAKDM4E | |
| SCHEMBL3589309 | 0.69 | L3MBTL3 (0.47) | NCF1ALDH1A1MAPTKMT2A | |
| SCHEMBL4697729 | 0.69 | HTR6 (0.49) | HTR2AHTR6KDM4EGAAALDH1A1 | |
| SCHEMBL6223934 | 0.69 | HTR3A (0.44) | HTR2AKMT2AHTR3AHRH4 | |
| SCHEMBL2013498 | 0.69 | ADRA2C (0.68) | ADRA2CKDM4EGAAALDH1A1MAPT | |
| SCHEMBL21574870 | 0.69 | GAA (0.52) | AGXTADRA2CKDM4EGAAALDH1A1 | |
| SCHEMBL3594477 | 0.68 | LMNA (0.61) | NCF1CHKAKDM4EALDH1A1 | |
| SCHEMBL13453374 | 0.67 | NOS3 (0.42) | AGXTNCF1ADRA2CCHKAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
| EP-2074127-A1 | PYRAZOLO [1, 5-A]PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | Novartis AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008037459-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AND THEIR THERAPEUTIC USE | NOVARTIS AG (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029636-A1 | Lck inhibitors | LCK, ZAP70, FYN | AGXT 4353/4885HTR2A 4538/4885HTR6 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.